COMMUNIQUÉS West-GlobeNewswire

-
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
21/10/2025 -
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
21/10/2025 -
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
21/10/2025 -
Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors
21/10/2025 -
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
21/10/2025 -
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
21/10/2025 -
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025 -
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/2025 -
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
21/10/2025 -
Step Pharma to spotlight work in CTPS2-null solid tumours at 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
21/10/2025 -
Acies Bio doubling biomanufacturing capacity with the construction of 30 m³ bioreactor
21/10/2025 -
Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO
21/10/2025 -
PrestoDoctor Expands Into Michigan Ahead of New Cannabis Tax Changes
21/10/2025 -
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
21/10/2025 -
Phonak’s AI revolution continues: new Infinio Ultra hearing aids with clearer sound and easier maintenance
21/10/2025 -
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
21/10/2025 -
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
21/10/2025 -
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
21/10/2025 -
Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy
20/10/2025
Pages